Business
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
CAMBRIDGE, Mass., October 27, 2025--Takeda announced the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S.
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":266,"url":"https://media.zenfs.com/en/business-wire.com/334775638f0a385c7fdd7e557fd5e946"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SJVnTXq7AarNBfdrbasByQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/334775638f0a385c7fdd7e557fd5e946","width":480,"height":266}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Dedicated Devices for HYQVIA [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] Reduce the Number of Steps and Ancillary Supplies Compared to a Pooling Bag When Preparing the HYQVIA Infusion1,2","length":219,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"HyHub and HyHub Duo Represent Takeda’s First Devices Customized for Use with a Plasma-Derived Therapy to Help Address Unmet Patient Needs","length":137,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":356,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., October 27, 2025--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are prescribed HYQVIA® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase]. The dedicated devices allow HYQVIA, a facilitated subcutaneous immunoglobulin (SCIg) infusion comprised of dual vial units (DVUs) of immunoglobulin and hyaluronidase, to be transferred from vials without using a needle or pooling bag in a home environment or clinical setting.3,4 HyHub and HyHub Duo simplify HYQVIA administration by reducing the number of steps to prepare the infusion of two DVUs or more.1","length":753,"tagName":"p"},{"type":"text","content":""We collaborated with patients self-infusing HYQVIA and infusion nurses, highlighting their collective need for a simplified preparation process, standardized ancillary supplies, and greater mobility during infusion," said Uthra Sundaram, senior vice president and head of Takeda’s U.S. Plasma-Derived Therapies Business Unit. "By listening closely to our patients and healthcare partners, we customized these devices to help streamline ...